Breaking News Instant updates and real-time market news.

ALPN

Alpine Immune Sciences

$6.90

-0.1 (-1.43%)

16:49
01/28/19
01/28
16:49
01/28/19
16:49

Biotechnology Value Fund reports 6.5% passive stake in Alpine Immune Sciences

In a regulatory filing, Biotechnology Value Fund disclosed a 6.5% stake in Alpine Immune, which represents about 1.2M shares. The filing does not allow for activism.

ALPN Alpine Immune Sciences
$6.90

-0.1 (-1.43%)

01/22/19
PIPR
01/22/19
NO CHANGE
Target $11
PIPR
Overweight
Alpine Immune Sciences target lowered to $11 placement dilution at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Alpine Immune Sciences to $11 from $12 to reflect dilition from the company's recent private placement. Alpine recently issued 4.7 million units at $5.37 comprised of one share and 0.39 warrants with a $12.74 strike price raising gross proceeds of $25.3M, Tenthoff tells investors in a research note. The analyst estimates Alpine now holds pro forma cash of $86M to advance its pipeline of proprietary variant Ig domains as novel immunotherapies. He reiterates an Overweight rating on the shares.
12/02/18
PIPR
12/02/18
NO CHANGE
Target $12
PIPR
Overweight
Alpine Immune Sciences' ALPN-101 active in GvHD, CTA by YE18, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Alpine (ALPN) presented two posters at ASH on proprietary variable Immunoglobulin Domain technology. In vivo data at ASH showed single doses enhanced survival in GvHD models compared to Bristol Myer's (BMY) Nujolix, he notes, adding that a CTA for ALPN-101 by YE18 should enable healthy volunteer data and lead to a Phase II GvHD start next year. The analyst also points out that Alpine presented novel Transmembrane ImmuneModulatory Proteins that can be engineered into T cells to enhance response in immunosuppressive environments. Importantly these strategies differ from TIP technology partnered to Kite (GILD) and offer further partnering opportunity, Tenthoff contends. He reiterates an Overweight rating and $12 price target on Alpine's shares.
11/11/18
PIPR
11/11/18
NO CHANGE
Target $12
PIPR
Overweight
Piper Jaffray bullish on Alpine after 'robust' ALPN-202 preclinical activity
Piper Jaffray analyst Edward Tenthoff notes that Alpine Immune Sciences presented two posters at SITC for immuno-oncology variable Immunoglobulin Domain candidates. The analyst points out that new preclinical data on ALPN-202, which co-engages PD-L1 and CTLA-4 to selectively stimulates CD28 on T-cells, demonstrated "robust" anti-tumor activity in vivo compared to single agent anti-PD-1 durvalumab. He believes SITC data indicated vIgDs unique co-engagement at the synpase generates superior anti-tumor activity, and says Alpine will file an IND on lead autoimmune vIgD ALPN-101 by year-end 2018 and could prove superior to Orencia with preclinical data at ASH. Tenthoff reiterates an Overweight rating and $12 price target on the shares.
09/27/18
09/27/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with an Overweight at JPMorgan. 2. UPS (UPS) initiated with a Sector Weight at KeyBanc. 3. Cigna (CI) initiated with an Overweight at Cantor Fitzgerald. 4. Restoration Robotics (HAIR) initiated with an Outperform at William Blair. 5. Alpine Immune Sciences (ALPN) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PRNB

Principia Biopharma

$29.88

0.7 (2.40%)

06:22
10/16/19
10/16
06:22
10/16/19
06:22
Syndicate
Principia Biopharma 7.5M share Spot Secondary priced at $28.00 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

EURN

Euronav NV

$10.72

-0.605 (-5.34%)

06:21
10/16/19
10/16
06:21
10/16/19
06:21
Recommendations
Euronav NV analyst commentary  »

Euronav a good play on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

BA

Boeing

$370.99

-2.05 (-0.55%)

, EADSY

Airbus

$0.00

(0.00%)

06:20
10/16/19
10/16
06:20
10/16/19
06:20
Periodicals
Entry date for Boeing's 777-8 depending on customer demand, Reuters reports »

The date of entry into…

BA

Boeing

$370.99

-2.05 (-0.55%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

XOG

Extraction Oil & Gas

$2.65

-0.05 (-1.85%)

06:19
10/16/19
10/16
06:19
10/16/19
06:19
Downgrade
Extraction Oil & Gas rating change  »

Extraction Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

CNI

Canadian National

$86.78

0.38 (0.44%)

06:19
10/16/19
10/16
06:19
10/16/19
06:19
Upgrade
Canadian National rating change  »

Canadian National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 21

    Nov

  • 22

    Nov

INOV

Inovalon

$15.04

0.2 (1.35%)

06:19
10/16/19
10/16
06:19
10/16/19
06:19
Initiation
Inovalon initiated  »

Citi starts Inovalon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAB

Wabtec

$67.83

1.185 (1.78%)

06:17
10/16/19
10/16
06:17
10/16/19
06:17
Initiation
Wabtec initiated  »

Wabtec initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 13

    Nov

ADBE

Adobe

$279.40

1.61 (0.58%)

06:15
10/16/19
10/16
06:15
10/16/19
06:15
Downgrade
Adobe rating change  »

Citi downgrades Adobe to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

  • 04

    Nov

PLMR

Palomar

$40.61

-0.26 (-0.64%)

06:13
10/16/19
10/16
06:13
10/16/19
06:13
Initiation
Palomar initiated  »

Palomar initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXSM

Axsome Therapeutics

$20.65

2.42 (13.27%)

06:12
10/16/19
10/16
06:12
10/16/19
06:12
Initiation
Axsome Therapeutics initiated  »

Axsome Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNBR

Sleep Number

$46.69

0.48 (1.04%)

06:11
10/16/19
10/16
06:11
10/16/19
06:11
Recommendations
Sleep Number analyst commentary  »

Sleep Number price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$86.78

0.38 (0.44%)

06:11
10/16/19
10/16
06:11
10/16/19
06:11
Upgrade
Canadian National rating change  »

Canadian National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 21

    Nov

  • 22

    Nov

PLMR

Palomar

$40.61

-0.26 (-0.64%)

06:10
10/16/19
10/16
06:10
10/16/19
06:10
Initiation
Palomar initiated  »

Palomar initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$218.42

3.27 (1.52%)

06:08
10/16/19
10/16
06:08
10/16/19
06:08
Downgrade
Canadian Pacific rating change  »

Canadian Pacific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

MCK

McKesson

$138.17

4.01 (2.99%)

, ABC

AmerisourceBergen

$83.18

1.6 (1.96%)

06:08
10/16/19
10/16
06:08
10/16/19
06:08
Recommendations
McKesson, AmerisourceBergen, Cardinal Health analyst commentary  »

Barclays ups McKesson…

MCK

McKesson

$138.17

4.01 (2.99%)

ABC

AmerisourceBergen

$83.18

1.6 (1.96%)

CAH

Cardinal Health

$47.93

1.16 (2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

I

Intelsat

$26.09

1.09 (4.36%)

06:05
10/16/19
10/16
06:05
10/16/19
06:05
Hot Stocks
Intelsat and Marlink extend partnership for maritime broadband services »

Intelsat and Marlink have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.00

0.145 (5.09%)

06:03
10/16/19
10/16
06:03
10/16/19
06:03
Recommendations
Foamix analyst commentary  »

Barclays likes Foamix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

TWTR

Twitter

$40.26

0.5 (1.26%)

06:03
10/16/19
10/16
06:03
10/16/19
06:03
Hot Stocks
Twitter clarifies when it will enforce rules against world leaders »

Twitter said in a blog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

MOH

Molina Healthcare

$117.37

4.885 (4.34%)

06:02
10/16/19
10/16
06:02
10/16/19
06:02
Hot Stocks
Molina Healthcare to acquire certain assets of YourCare Health Plan for $40M »

Molina Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

FBM

Foundation Building Materials

$17.55

0.11 (0.63%)

06:01
10/16/19
10/16
06:01
10/16/19
06:01
Upgrade
Foundation Building Materials rating change  »

Foundation Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBSH

Commerce Bancshares

$60.24

0.87 (1.47%)

06:00
10/16/19
10/16
06:00
10/16/19
06:00
Earnings
Commerce Bancshares reports Q3 EPS 98c, consensus 92c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APDN

Applied DNA Sciences

$0.18

-0.0264 (-12.57%)

05:59
10/16/19
10/16
05:59
10/16/19
05:59
Hot Stocks
Applied DNA Sciences enters partnership with Molecular Isotope Technologies »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

GOOG

Alphabet

$1,243.53

25.3 (2.08%)

, GOOGL

Alphabet Class A

$1,242.51

24.9 (2.05%)

05:59
10/16/19
10/16
05:59
10/16/19
05:59
Periodicals
Google staff fighting over decision to ban protest video game app, Vox reports »

Google employees are…

GOOG

Alphabet

$1,243.53

25.3 (2.08%)

GOOGL

Alphabet Class A

$1,242.51

24.9 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

JNJ

Johnson & Johnson

$132.84

2.17 (1.66%)

05:59
10/16/19
10/16
05:59
10/16/19
05:59
Upgrade
Johnson & Johnson rating change  »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLND

Millendo Therapeutics

$7.12

0.04 (0.56%)

05:55
10/16/19
10/16
05:55
10/16/19
05:55
Conference/Events
Millendo Therapeutics management to meet with SVB Leerink »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.